Latest Adenosine A2A receptor Stories
WELWYN GARDEN CITY, England, May 9, 2011 /PRNewswire/ -- - Best-in-Class Candidate With Potential in Treatment of CNS Diseases Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.
Scientists from The Scripps Research Institute have determined a new structure from a medically important superfamily of proteins.
Researchers have determined the structure of a protein that helps guide blood-forming stem cells, or hematopoetic stem cells.
- A trick or prank.